Leo Lines Up PellePharm Buy In Rare Skin Cancer Deal
The Danish dermatology specialist could be hitting the acquisition trail again soon having taken an option to buy BridgeBio's PellePharm and its skin cancer drug patidegib in a deal that could be worth $760m.
You may also be interested in...
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.